Overactive Bladder
- PO (Adults): Tablets: 5 mg once daily, may ↑ to 10 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Tablets: Not to exceed 5 mg once daily.
Renal Impairment
- PO (Adults): CCr <30 mL/min: Tablets: Not to exceed 5 mg once daily.
Hepatic Impairment
- PO (Adults): Moderate hepatic impairment: Tablets: Not to exceed 5 mg once daily.
Neurogenic Detrusor Overactivity
- PO (Children
2 yr and >60 kg): Suspension: 5 mg once daily, may ↑ to 10 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Suspension: Not to exceed 5 mg once daily. - PO (Children 2 yr and 46–60 kg): Suspension: 4 mg once daily, may ↑ to 8 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Suspension: Not to exceed 4 mg once daily.
- PO (Children 2 yr and 31–45 kg): Suspension: 3 mg once daily, may ↑ to 6 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Suspension: Not to exceed 3 mg once daily.
- PO (Children 2 yr and 16–30 kg): Suspension: 3 mg once daily, may ↑ to 5 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Suspension: Not to exceed 3 mg once daily.
- PO (Children 2 yr and 9–15 kg): Suspension: 2 mg once daily, may ↑ to 4 mg once daily; Concurrent use of strong CYP3A4 inhibitors: Suspension: Not to exceed 2 mg once daily.
Renal Impairment
- PO (Children 2 yr): CCr <30 mL/min: >60 kg: Not to exceed 5 mg once daily (suspension); 46–60 kg: Not to exceed 4 mg once daily (suspension); 16–45 kg: Not to exceed 3 mg once daily (suspension); 9–15 kg: Not to exceed 2 mg once daily (suspension).
Hepatic Impairment
- PO (Children 2 yr): Moderate hepatic impairment: >60 kg: Not to exceed 5 mg once daily (suspension); 46–60 kg: Not to exceed 4 mg once daily (suspension); 16–45 kg: Not to exceed 3 mg once daily (suspension); 9–15 kg: Not to exceed 2 mg once daily (suspension).